Literature DB >> 18053422

Plasmin and matrix metalloproteinase system in deep venous thrombosis resolution.

Peter K Henke1.   

Abstract

Deep venous thrombosis (DVT) is a common event in hospitalized medical and surgical patients. Outside of anticoagulation, few good options exist for decreasing the vein wall damage that results after natural thrombolysis. DVT resolution is complex and involves chemokines, leukocytes, and native vein wall cells. Herein some aspects of DVT resolution related to the intersection of inflammation, the plasminogen and matrix metalloproteinase systems, and their respective inhibitors are reviewed. Ultimately, better knowledge of these natural thrombolytic systems may allow local, directed, and specific acceleration of DVT resolution and decreased vein wall damage.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18053422     DOI: 10.2310/6670.2007.00050

Source DB:  PubMed          Journal:  Vascular        ISSN: 1708-5381            Impact factor:   1.285


  4 in total

1.  Induction of heme oxygenase-1 is a beneficial response in a murine model of venous thrombosis.

Authors:  Michal J Tracz; Julio P Juncos; Joseph P Grande; Anthony J Croatt; Allan W Ackerman; Zvonimir S Katusic; Karl A Nath
Journal:  Am J Pathol       Date:  2008-11-06       Impact factor: 4.307

Review 2.  Cytokines, Adhesion Molecules, and Matrix Metalloproteases as Predisposing, Diagnostic, and Prognostic Factors in Venous Thrombosis.

Authors:  Knut A Mosevoll; Silje Johansen; Øystein Wendelbo; Ina Nepstad; Øystein Bruserud; Håkon Reikvam
Journal:  Front Med (Lausanne)       Date:  2018-05-22

Review 3.  Inflammation in Cerebral Venous Thrombosis.

Authors:  Jiayue Ding; Baoying Song; Xiran Xie; Xaingyu Li; Zhiying Chen; Zhongao Wang; Liqun Pan; Duo Lan; Ran Meng
Journal:  Front Immunol       Date:  2022-04-04       Impact factor: 8.786

4.  Sepsis-induced thrombus formation and cell-specific HIFs.

Authors:  Colin E Evans; Addie B Spier; You-Yang Zhao
Journal:  Thromb Res       Date:  2018-08-31       Impact factor: 3.944

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.